Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 11Carcinoma, Hepatocellular 10Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasms 6Melanoma 4Endometrial Neoplasms 3Uveal Melanoma 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Liver Neoplasms 2Kidney Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Adenoid Cystic 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Clear Cell Carcinoma 1Non-squamous Non-small-cell Lung Cancer 1NSCLC 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1

Interventions

Oxaliplatin 7Fluorouracil 7Leucovorin 6pembrolizumab 4Paclitaxel 4Capecitabine 4Radiotherapy 3Radiation 3Nivolumab 3Cisplatin 3zimberelimab 2tislelizumab 2durvalumab 2Trastuzumab 2Taxes 2Levoleucovorin 2Irinotecan 2zanidatamab 1tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1spartalizumab 1quemliclustat 1obinutuzumab 1naptumomab estafenatox 1lenvatinib 1futibatinib 1dehydroftorafur 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma Of Esophagus × lenvatinib × Clear all
NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
3 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡